Every 8-K that Eledon Pharmaceuticals Inc (ELDN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ELDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELDN filings page.
Eledon Pharmaceuticals reported second quarter 2026 results and highlighted progress with its lead anti-CD40L antibody, tegoprubart. An End-of-Phase 2 meeting with the FDA supports advancing a global Phase 3 kidney transplantation trial enrolling approximately 600 patients, with non-inferiority to tacrolimus at 52 weeks as the primary endpoint. Long-term Phase 2 BESTOW data showed mean eGFR of 74 vs. 61 mL/min/1.73 m² for tegoprubart versus tacrolimus at 18 months, with no biopsy-proven acute rejection events after six months in tegoprubart-treated patients. In an islet cell transplantation study, all 12 patients with type 1 diabetes achieved insulin independence and HbA1c below 6.5%. Cash, cash equivalents and short-term investments were $88.8 million as of June 30, 2026, and the company expects this to fund operations into the second quarter of 2027. R&D expense was $18.2 million, G&A was $4.6 million, and net loss was $31.6 million, including a $9.6 million non-cash loss from warrant liability remeasurement.
Eledon Pharmaceuticals, Inc. reported that stockholders approved key actions at the June 18, 2026 annual meeting. Investors voted to amend the company’s Restated Certificate of Incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares, and the company filed a Certificate of Amendment in Delaware effective June 22, 2026.
Stockholders also elected David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson as Class III directors for terms ending at the 2029 annual meeting. In addition, they ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
Eledon Pharmaceuticals reported first quarter 2026 results and progress for its lead antibody tegoprubart. In an investigator-led islet transplant study, all 10 patients who were more than four weeks post-transplant achieved 100% insulin independence with no graft rejection or typical tacrolimus-related toxicities. Tegoprubart also received FDA Orphan Drug designation for preventing allograft rejection in liver transplantation.
In kidney transplantation, 24‑month Phase 1b extension data in eight patients showed no biopsy‑proven acute rejection, graft loss, death, new-onset diabetes, or de novo donor‑specific antibodies, and mean eGFR improved from 67.0 to 74.2 mL/min/1.73 m². Cash, cash equivalents and short‑term investments were $111.1 million as of March 31, 2026, which the company believes will fund operations into the second quarter of 2027.
R&D expenses were $17.2 million versus $13.5 million a year earlier, while G&A was $4.0 million versus $4.4 million. Net loss was $39.0 million, or $0.33 per common share, compared with $6.5 million, or $0.08 per share, mainly due to a $19.0 million non‑cash loss from warrant liabilities versus a $10.1 million non‑cash gain in 2025; excluding these, net loss was $20.1 million versus $16.6 million.
Eledon Pharmaceuticals reported fourth quarter and full year 2025 results and highlighted progress for its lead antibody tegoprubart in multiple transplant settings. The FDA granted Orphan Drug designation for preventing allograft rejection in liver transplantation, adding to prior orphan designations in islet cell transplantation and ALS.
In a Phase 1b kidney transplant extension study, eight patients followed for 24 months had no biopsy-proven acute rejection, graft loss, death, new-onset diabetes, or de novo donor-specific antibodies, while mean eGFR rose from 67.0 to 74.2 mL/min/1.73 m². In a UChicago islet transplant trial for type 1 diabetes, all 10 evaluable patients achieved insulin independence with most recent HbA1c below 6.0% and a mean of about 5.35%, with no rejection or typical tacrolimus-related toxicities.
For 2025, research and development expenses were $66.3 million versus $52.0 million in 2024, and general and administrative expenses were $17.0 million versus $18.6 million. Net loss was $45.6 million, or $0.52 per common share, compared to a $36.2 million loss, or $0.66 per share, in 2024. Results included non-cash gains from changes in warrant liabilities of $33.4 million in 2025 and $30.9 million in 2024.
Eledon Pharmaceuticals announced an underwritten public offering of 15,152,485 shares of common stock at $1.65 per share and pre-funded warrants priced at $1.649 each, exercisable for up to 15,151,515 shares at an exercise price of $0.001 per share.
The underwriters have a 30‑day option to purchase up to 4,545,600 additional shares. Estimated net proceeds to the company are approximately $46.5 million, or $53.6 million if the option is exercised in full. Closing is expected on November 13, 2025, subject to customary conditions. Eledon plans to use proceeds to support continued clinical development, advance pipeline programs, and for general corporate purposes.
Certain officers and directors agreed to 60‑day lock‑ups from November 12, 2025. Pre‑funded warrants include a beneficial ownership cap of 4.99% (or 9.99% at holder election), adjustable with 61 days’ notice, not to exceed 19.99% to comply with Nasdaq rules.
Eledon Pharmaceuticals furnished an 8-K announcing an estimated $93.4 million in cash, cash equivalents, and short-term investments as of September 30, 2025. The company described this figure as unaudited, preliminary, and subject to completion of financial closing procedures and management review.
Eledon also disclosed it issued a press release with results from its Phase 2 BESTOW trial evaluating tegoprubart in de novo kidney transplant patients, and plans a conference call on November 7, 2025 to discuss updated data. The 8-K states the Item 2.02 and Item 7.01 information, including the press release, is being furnished and not filed under the Exchange Act.
Date: August 6, 2025.
Eledon Pharmaceuticals, Inc. (ELDN) disclosed updated data from its ongoing Phase 1b open-label trial of tegoprubart for the prevention of organ rejection in kidney transplant patients. The results were presented at the World Transplant Congress in San Francisco, CA. The company issued a press release (attached as Exhibit 99.1) and hosted a conference call on the same date. The presentation for the call will be posted on the company investor site at https://ir.eledon.com/investor-relations prior to the call.
The filing notes that the Item 7.01 disclosure and Exhibit 99.1 are not deemed "filed" under Section 18 of the Exchange Act and are not incorporated by reference into Securities Act or Exchange Act filings unless expressly stated.